Cellumen, Inc. Partners with Alzheimer’s Drug Discovery Foundation to Develop New Assays for Early Treatment of Alzheimer’s

September 30, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

PITTSBURGH--(BUSINESS WIRE)--Cellumen, Inc. today announced an agreement with the Alzheimer’s Drug Discovery Foundation (ADDF) to apply Cellumen’s Cellular Systems Biology (CSB) technology to create a cellular model of Alzheimer’s disease.

Twitter
LinkedIn
Facebook
Email
Print

Alliances